Comparative Study of Combined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata

Alopecia areata (AA) is an immunologically mediated disease characterized by non-scarring hair loss (Madni and Shapiro, 2000). AA is presented by rapid and complete hair loss in one or more round or oval patches, usually on the scalp, beard area, eyebrows, eyelashes, and less commonly, on other hairy areas of the body (Berker et al., 2010 and James et al., 2011) Alopecia areata is a T-cell-mediated autoimmune disease. There is a complicated interplay between loss of immune privilege in the hair follicle, autoimmune-mediated hair follicle damage, and activation of inflammatory pathways that have been argued to explain the development of this disorder, but the exact pathophysiology of AA remains unknown. Hair follicles are infiltrated by autoreactive CD8 and CD4 T lymphocytes, which attack hair follicle-derived autoantigens while sparing the stem compartment (Rajabi et al., 2018).
Alopecia areata can be treated with topical and/or intralesional corticosteroids, which are the treatment of choice. Anthralin, minoxidil, coal tar, and topical immunotherapy are examples of other topical treatments. Systemic immunosuppressants such as cyclosporine, systemic steroids, Janus kinase inhibitors, and methotrexate may be considered in severe resistant cases (lee and lee, 2017).
Intralesional triamcinolone acetonide is preferred in cases of AA , as it is well known as anti-inflammatory and interferes with local immunity of the skin, which helps in the recovery of the disease, but if used in wrong technique or given in a high dose, it might cause all the side effects of corticosteroid, especially skin atrophy (Berker et al., 2010).
Lactic acid is a member of alpha-hydroxy acids. It has been used in the treatment of many skin diseases, like AA and vitiligo. Lactic acid stimulates spontaneous secretion of vascular endothelial growth factor (VEGF) by human reconstructed epidermis. VEGF is an angiogenic cytokine involved in angiogenesis and wound healing and stimulates the growth of hair follicles resulting in recovery of AA. Other studies suggest that lactic acid may act through its irritant effect (Al-Tammimy, 2005).
Vitamin D interacts with the innate and adaptive immune systems in a variety of ways, the majority of which contribute to its downregulation (Nancy and Yehuda, 2009). It has a powerful effect on T and B lymphocytes, influencing their activation responses (Arnson et al., 2007).
All cells of the immune system express 1,25-dihydroxyvitamin D3 receptors (VDRs) and are therefore vulnerable to calcitriol-mediated modulation. Vitamin D3 has the ability to influence the migration and maturation of different dendritic cell subtypes and their production of chemokines and cytokines, giving them an immunoregulatory and tolerogenic role (Illescas-Montes et al., 2019) It has been shown that VDRs are highly expressed in the keratinocytes of human hair follicles and the absence of their expression is associated with reduced hair follicle growth and epidermal differentiation. Reduced VDR expression in the hair follicles of affected areas has also been observed in studies of AA patients' scalp (Çerman et al., 2015).
Microneedling (MN) is a technique that comprises puncturing the skin repeatedly with sterile microneedles (Iriarte et al., 2017). It promotes hair regeneration by triggering stem cells in the hair bulge, which results in the generation of growth factors. It also improves blood circulation to the hair follicles and influences the local immune cells (Chandrashekar et al., 2014). Moreover, combining MN with applied topical drugs facilitates their absorption through the microchannels created within the epidermis (Fertig et al., 2018).

开始日期2023-12-15

申办/合作机构

Zagazig University

JPRN-UMIN000052725 / Suspended

Study on Improvement of Intestinal Environment and Defecation by Intake of lactic acid bacillus A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study - Study on Improvement of Intestinal Environment and Defecation by Intake of lactic acid bacillus A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study

开始日期2023-11-07

申办/合作机构-

JPRN-UMIN000051940 / SuspendedN/A

Double-blind study to confirm the effect of lactic acid bacteria N1487-7 on improving liver function -Placebo-controlled, double-blind, randomized, parallel-group comparative study- - Double-blind study to confirm the effect of lactic acid bacteria N1487-7 on improving liver function -Placebo-controlled, double-blind, randomized, parallel-group comparative study-

开始日期2023-09-12

申办/合作机构-

100 项与乳酸相关的临床结果

登录后查看更多信息

100 项与乳酸相关的转化医学

登录后查看更多信息

100 项与乳酸相关的专利（医药）

登录后查看更多信息

3,458

项与乳酸相关的文献（医药）

2024-03-01·Animal nutrition (Zhongguo xu mu shou yi xue hui)

Zinc lactate alleviates oxidative stress by modulating crosstalk between constitutive androstane receptor signaling pathway and gut microbiota profile in weaned piglets

Article

作者: Tang, Wenjie ; Xiang, Xuan ; Wang, Houfu ; Zhou, Wentao ; He, Liuqin ; Yin, Yulong ; Li, Tiejun

This study aimed to determine the regulatory mechanism of dietary zinc lactate (ZL) supplementation on intestinal oxidative stress damage in a paraquat (PQ)-induced piglet model. Twenty-eight piglets (mean body weight 9.51 ± 0.23 kg) weaned at 28 d of age were randomly divided into control, ZL, PQ, and ZL + PQ groups (n = 7 in each group). The ZL-supplemented diet had little effect on growth performance under normal physiological conditions. However, under PQ challenge, ZL supplementation significantly improved average daily gain (P < 0.05) and reduced the frequency of diarrhea. ZL improved intestinal morphology and ultrastructure by significantly increasing the expression level of the jejunal tight junction protein, zonula occludens-1 (ZO-1) (P < 0.05), and intestinal zinc transport and absorption in PQ-induced piglets, which reduced intestinal permeability. ZL supplementation also enhanced the expression of antioxidant and anti-inflammatory factor-related genes and decreased inflammatory cytokine expression and secretion in PQ-induced piglets. Furthermore, ZL treatment significantly inhibited the activation of constitutive androstane receptor (CAR) signaling (P < 0.01) in PQ-induced piglets and altered the structure of the gut microbiota, especially by significantly increasing the abundance of beneficial gut microbes, including UCG_002, Ruminococcus, Rikenellaceae_RC9_gut_group, Christensenellaceae_R_7_group, Treponema, unclassified_Christensenellaceae, and unclassified_Erysipelotrichaceae (P < 0.05). These data reveal that pre-administration of ZL to piglets can suppress intestinal oxidative stress by improving antioxidant and anti-inflammatory capacity and regulating the crosstalk between CAR signaling and gut microbiota.

2024-02-07·Neuroscience

Acute Administration of Lactate Exerts Antidepressant-like Effect Through cAMP-dependent Protein Synthesis.

Article

作者: Liang Zhang ; Jing Zheng ; Shi-Yan Liu ; Li-Li Hou ; Bo Zhang ; Shao-Wen Tian

Lactate acts as an important metabolic substrate and signalling molecule modulating neural activities in the brain, and recent preclinical and clinical studies have revealed its antidepressant effect after acute or chronic peripheral administration. However, the neural mechanism underlying the antidepressant effect of lactate, in particular when lactate is acutely administered remains largely unknown. In the current study, we focused on forced swimming test (FST) to elucidate the neural mechanisms through which acute intracerebroventricular (ICV) infusion of lactate exerts antidepressant-like effect. A total of 238 male Sprague Dawley rats were used as experimental subjects. Results showed lactate produced antidepressant-like effect, as indicated by reduced immobility, in a dose- and time-dependent manner. Moreover, the antidepressant-like effect of lactate was dependent of new protein synthesis but not new gene expression, lactate's metabolic effect or hydroxy-carboxylic acid receptor 1 (HCAR1) activation. Furthermore, lactate rapidly promoted dephosphorylation of eukaryotic elongation factor 2 (eEF2) and increased brain-derived neurotrophic factor (BDNF) protein synthesis in the hippocampus in a cyclic adenosine monophosphate (cAMP)-dependent manner. Finally, inhibition of cAMP production blocked the antidepressant-like effect of lactate. These findings suggest that acute administration of lactate exerts antidepressant-like effect through cAMP-dependent protein synthesis.

2024-02-07·Cell reports

Lactic acid induces transcriptional repression of macrophage inflammatory response via histone acetylation.

Article

作者: Weiwei Shi ; Tiffany J Cassmann ; Aditya Vijay Bhagwate ; Taro Hitosugi ; W K Eddie Ip

Lactic acid has emerged as an important modulator of immune cell function. It can be produced by both gut microbiota and the host metabolism at homeostasis and during disease states. The production of lactic acid in the gut microenvironment is vital for tissue homeostasis. In the present study, we examined how lactic acid integrates cellular metabolism to shape the epigenome of macrophages during pro-inflammatory response. We found that lactic acid serves as a primary fuel source to promote histone H3K27 acetylation, which allows the expression of immunosuppressive gene program including Nr4a1. Consequently, macrophage pro-inflammatory function was transcriptionally repressed. Furthermore, the histone acetylation induced by lactic acid promotes a form of long-term immunosuppression ("trained immunosuppression"). Pre-exposure to lactic acid induces lipopolysaccharide tolerance. These findings thus indicate that lactic acid sensing and its effect on chromatin remodeling in macrophages represent a key homeostatic mechanism that can provide a tolerogenic tissue microenvironment.

项与乳酸相关的新闻（医药）

2024-03-20

·PRNewswire

Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal

— Medi-Cal serves more than 15.4 million Californians — — 7.4% improvement in Phexxi rebate to take effect July 1, 2024 — SAN DIEGO, March 20, 2024 /PRNewswire/ -- Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that it has successfully renegotiated the rebate for Phexxi® (lactic acid, citric acid and potassium bitartrate), its hormone-free, woman-controlled contraceptive, with Medi-Cal, the California state Medicaid program. Phexxi is the first and only locally-acting contraceptive gel approved by the FDA. It is applied zero-to-60 minutes before intercourse and works, without hormones, by maintaining the natural vaginal biome with a pH that is naturally inhospitable to sperm. Medi-Cal is funded by the California Department of Health Care Services, the largest health care purchaser in the state, and serves more than 15.4 million beneficiaries. The renegotiated rebate improves Evofem's rebate on Medi-Cal prescriptions by 7.4%, while affording price protection to Medi-Cal against future Phexxi WAC increases. The new rebate will take effect July 1, 2024. The vaginal pH modulator continues to be included on the Medi-Cal Rx Family Planning, Access, Care, and Treatment Pharmacy Formulary. Medi-Cal beneficiaries may receive one box of 12 single-use Phexxi applicators per dispensing, and up to three boxes in any 75-day period. Evofem recently entered into a definitive agreement to be acquired by Aditxt, Inc. (Nasdaq: ADTX). Evofem believes the contemplated transaction represents a compelling opportunity to accelerate its growth trajectory, as a subsidiary of Aditxt, into a multi-product women's health franchise. The companies are working toward close in the second half of 2024. About Evofem Biosciences Evofem Biosciences, Inc., is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com. Phexxi® is a registered trademark of Evofem Biosciences, Inc. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the expected effective date of the Medi-Cal rebate and the anticipated benefits of the contemplated Aditxt transaction and timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 27, 2023, Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC on November 14, 2023 and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Contact Amy Raskopf Evofem Biosciences, Inc. [email protected] (917) 673-5775 SOURCE Evofem Biosciences, Inc.

并购上市批准

2024-03-13

·美通社

适乐肤、理肤泉等品牌亮相美国皮肤科学会年会

汇聚前沿科学力量共绘皮肤健康之美上海2024年3月13日 /美通社/ -- 第82届美国皮肤科学会 (American Academy Of Dermatology简称：AAD) 年会于2024年3月8日-12日在圣地亚哥成功举办，AAD年会作为全球皮肤科领域规模最大、最具影响力和代表性的国际学术盛会之一，一直受到来自各国皮肤领域专家的关注。本次大会囊括了300多个皮肤相关的专题会议，吸引了全球超过20,000万名业内人士，及超过400家参展公司参与。欧莱雅集团皮肤科学美容事业部旗下适乐肤、理肤泉、修丽可、薇姿等品牌重磅亮相，以科学、专业的护肤解决方案持续引领健康之美。欧莱雅集团皮肤科学美容事业部旗下品牌重磅亮相第82届美国皮肤科学会年会适乐肤 CeraVe ：汇聚专业力量，共筑健康屏障在全美皮肤学专家推荐护肤品牌中处于遥遥领先的适乐肤CeraVe专注于皮肤屏障的修护，并在短短几年内迅速崛起，获得了美国皮肤科医生的一致推荐。在本次大会上，适乐肤重磅公布了其皮肤屏障研究——BRaCE研究的最新成果。适乐肤坚持立足于皮肤科学，专注皮肤屏障研究，持续深耕医学领域。在AAD2024展台现场，适乐肤围绕皮肤屏障开展了多场科学研究，联合欧莱雅研发中心，深入探讨了皮肤屏障中神经酰胺的含量和亚型与皮肤疾病患者生存状态的问题。适乐肤所有产品都联合了皮肤学专家进行研发。在美国，其产品线覆盖了各种皮肤问题，甚至细分到了糖尿病患者皮肤并发症、银屑病、急救治疗等领域。 AAD2024会议现场适乐肤展台于此同时，适乐肤在中国最新推出的氨心洁面（适乐肤积雪草舒缓高保湿洁面乳）也被带到了AAD2024会议现场，这款专为中国人群开发的洁面在品牌核心成分三重神经酰胺的基础上，搭配积雪草提取物，独创双态液晶氨基酸型表活，打造皮肤舒缓配方，在保持卓效清洁力的同时，实现肤感上的干爽水润。在展台试用期间，即便该产品是专为中国人群皮肤特质研发的，其温和舒缓和有效的清洁力也获得了诸多美国皮肤学专家的大力好评。自2018年进入中国后，适乐肤深入了解大众对于屏障修护的需求，不断建立大众消费者对品牌新品的产品认知，通过明星产品，扩大品牌知名度，强化品牌专业医学形象。在过去五年，适乐肤不仅在中国连续多年实现高速增长，还打造了神酰C乳、修护C霜、水杨酸洁面等王牌产品，成为欧莱雅集团中国增速最快的品牌。品牌通过携手权威皮肤学专家，深入了解和结合临床案例，开展科学研究，加强医学循证，践行"专研修护，共御健康屏障"的品牌使命，在中国的短短几年就发布《2022皮肤屏障健康蓝宝书》和20余篇学术论文及壁报成果。不仅如此，适乐肤携手行业顶尖合作伙伴，如领先生物医药公司诺华、赛诺菲，共建皮肤屏障生态圈，不断探索服务屏障受损人群的新模式，以惠及更多有皮肤问题的人群。理肤泉 La Roche-Posay ：专研皮肤科学，共探皮肤健康新未来理肤泉，作为全球领先的皮肤学级科学护肤品牌，于此次AAD2024携诸多研究成果和重磅新品亮相，并与来自世界各地的皮肤学专家分享品牌的前沿研究与学术成果。理肤泉携诸多研究成果和重磅新品亮相AAD2024 值此AAD2024，理肤泉携手全球顶级皮肤科专家共赴大会现场，并发布了20篇学术壁报和3场口头报告。壁报主题横跨色素性皮肤病、痤疮、特应性皮炎、光生物学、非黑色素瘤皮肤癌及其他皮肤疾病七大类目，展示了品牌针对痤疮、炎症后色沉等皮肤疾病的前沿研究，痤疮及肿瘤疾病管理国际顶级专家共识及产品相关临床试验成果。大会期间，理肤泉还开展多场品牌科学演讲，主题涵盖色素性疾病的最新发现、广谱防晒霜的功效评估、炎症后色沉的大型流调结果分享等，向众多品牌好友和皮肤学专家分享皮肤科学研究的新发现，共同探讨皮肤学研究新趋势，协力为饱受皮肤问题困扰的人群提供更为安全有效的解决方案。理肤泉始终坚持在皮肤科学研究领域深耕，致力于前沿的皮肤科学研究，旨在通过皮肤科学领域的创新科技以创造更有效的皮肤问题解决方案，进而提高人们的生活质量，共倡"皮肤科学，改变生活"。不仅止步于皮肤科学领域的研究突破，理肤泉品牌长期以来也持续关注受到皮肤问题困扰的人群，并提供切实有效的问题解决方案。理肤泉"蓝丝带"关爱皮肤健康项目一直以来都在行动，呼吁更多人关注皮肤问题，用"科学与爱（MEDICAL&LOVE）"传递温暖守护皮肤健康，关爱更多需要被帮助的人群及家庭。修丽可 SkinCeuticals® ：抗氧科学先锋，领航整全护肤修丽可作为抗氧化科学和整全护肤的引领者，在本次AAD2024上分享了全新产品的科学理念以及整全护肤的临床成果。大会壁报将呈现了来自全球的整全护肤指南、整全护肤临床研究以及新产品前沿的抗衰老试验结果。与全球专家共同创作的四张修丽可壁报为：整全护肤： 1) 口头报告：整全护肤的实践指南以提高患者对能量源性设备治疗的的疗效和满意度——Drs. Edward Lain , Andrew F Alexis, Valeria Campos , Ariel Haus , Jihee Kim , Mark Lupin, Cara McDonald , Cheng-Feng Zhang 2) 一种含有牛磺酸、植酸、扁桃酸、水杨酸和乳酸的新型角质剥脱剂用于改善面部光老化和光损伤——Dr. Lain. 研究与创新： 3) Cell Catalyst: 一种含牛磺酸和多酸的新型抗衰精华的疗效 4) A.G.E. 眼霜: 一种富含类黄酮眼霜对所有肤色人群的抗衰老作用此外，修丽可也举办了一场精心筹备的抗氧化研讨会，重点讨论 CEF的卓越科学。演讲嘉宾 Dr. Lisa Ginn、Dr. Giuseppe Valacchi 和 Dr. Mark Lupin 共同向参会者介绍抗氧化科学的最新进展，包括抗氧化剂对抗环境侵害的作用，除紫外线防护外仍需要抗氧化剂的重要性，以及讨论如何将抗氧化剂与医美项目结合的应用。修丽可与全球专家共同创作四张修丽可壁报薇姿 Dercos ：中外共话头皮毛发健康管理作为专业的头皮毛发护理领导品牌，薇姿在本次AAD2024中成立了美国皮肤学专家专业委员会，并重磅发布3篇研究成果，以学术壁报的形式与来自世界各地参会的皮肤科专家进行学术交流。薇姿在AAD2024中与来自世界各地参会的皮肤科专家进行学术交流 1) 含1%二硫化硒的洗发水与2%酮康唑洗剂对中重度头皮脂溢性皮炎患者疗效的随机对照临床研究评估——Daniel Fernandes Melo, Sergio Vañó-Galván， Anna Veriato , Vimi Lutchmanen-Kolanthan, Beatriz Sant 'Anna, Stéphanie Leclerc-Mercier, Victoria Barbosa , Pascal Reygagne 2) 头发生态系统的全球认知解码：头发纤维、毛囊和头皮。一项在6个国家进行的试点研究，共纳入12624名男性或女性受试者——Frederic Flament; Aurelie. Maudet; Anthony Galliano1; Philippe Barbarat; Meriem Jabnoun; Stephanie Leclerc-Mercier ; Audrey Imbert Legrain ; Laurence Lebarbanchon 3) 含二硫化硒的洗发水对任何皮肤光型和头皮类型且有头屑的受试者的益处——Pascal Reygagne, Anna Veriato , Claire Deloche , Stephanie Leclerc-Mercier , Beatriz Sant 'Anna, Victoria Barbosa。此外，著名美妆博主、皮肤科医生哈佛一哥Dr.Jeff受品牌邀请与国际级皮肤科专家Michelle Pratt医生, Bianca Maria Piraccini医生进行专业对话，探讨全球头皮毛发健康管理蓬勃发展的趋势下，现阶段皮肤科医生、头皮毛发患者及消费者未被满足的需求、未来最热门及最流行的趋势、以及改善或辅助治疗头皮毛发问题有效的成分、技术及医美手段。未来，薇姿将为有头皮毛发问题的人群提供更专业、更全面、更有效的头皮毛发健康管理方案。关于美国皮肤科学会美国皮肤科学会（American Academy of Dermatology，AAD）成立于1938年，是众多皮肤病协会中最具影响力及代表性的皮肤病专业学会。全球拥20,500多名医生会员，致力于促进皮肤、头发和指甲的诊断和医疗、外科和美容治疗；在皮肤科的临床实践、教育和研究中提倡高标准。

医药出海

2024-03-07

·PRNewswire

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

-- New weight loss drugs like Ozempic, Wegovy and Zepbound may make oral birth control pills less effective at certain points -- SAN DIEGO, March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States, with more than nine million prescriptions for Ozempic, Wegovy, Mounjaro, and similar diabetes and obesity drugs written during the last three months of 2022 alone.1 Zepbound weekly prescriptions hit 25,000 in December 2023, just one month after it was approved to treat obesity.2 These drugs may make oral birth control pills less effective at certain points in the dosing schedule, making an unintended pregnancy more likely. Eli Lilly's Mounjaro and Zepbound, which contain the same compound, clearly instruct prescribers to "advise females using oral contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation."3 Patients are cautioned that "birth control pills may not work as well," and that their "healthcare provider may recommend another type of birth control…"4 "The use of GLP-1 agonists to help women lose weight has become more prevalent," noted Lisa Rarick, M.D., FACOG, an OB-GYN working in Washington D.C. "For women who take oral contraceptives in conjunction with these medications, it is imperative they be counseled on options for back-up contraception, since many of these medications could interact with oral contraceptives, making them less effective. This highlights the critical need for a non-systemic, non-hormonal method, like Phexxi, to prevent unintended pregnancy." Users of oral birth control considering GLP-1 treatment are encouraged to plan ahead to prevent unintended pregnancy. Having a contraceptive strategy in place and the right product at your fingertips enables spontaneous intimacy no matter where you are in your GLP-1 dosing schedule. An on-demand, hormone-free method is a logical choice to provide these patients additional protection they need. One such option, Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, puts the power in her hands and with an FDA-approved contraceptive that she uses only when she needs it. The company behind Phexxi, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), recently entered into a definitive agreement to be acquired by Aditxt, Inc. (Nasdaq: ADTX). Evofem believes the contemplated transaction represents a compelling opportunity to accelerate its growth trajectory, as a subsidiary of Aditxt, into a multi-product women's health franchise. The companies are working toward a mid-2024 close. About Evofem Biosciences Evofem Biosciences is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com. Phexxi® is a registered trademark of Evofem Biosciences, Inc. Sources 1 Trilliant Health report September 2023. 2 Reuters 'Lilly CEO says weight-loss drug Zepbound weekly prescriptions hit 25,000 in December.' 1/8/2024 3 Zepbound Prescribing Information. 4 Zepbound Safety Summary with Warnings. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, including, without limitation, the anticipated benefits of the contemplated Aditxt transaction and timing thereof. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on April 27, 2023, Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC on November 14, 2023 and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. Media Contact [email protected] Investor Contact Amy Raskopf Evofem Biosciences, Inc. [email protected] Mobile: (917) 673-5775 SOURCE Evofem Biosciences, Inc.

并购上市批准

100 项与乳酸相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00111	-	G01AD01	DB04398

研发状态

适应症	最高研发状态	国家/地区	公司
-	批准上市	中国更多	-
疼痛	临床2期	俄罗斯更多	Stayble Therapeutics AB 更多
背痛	临床2期	-	Stayble Therapeutics AB 更多
椎间盘疾病	临床1期	波兰更多	Stayble Therapeutics AB 更多
腰痛	临床1期	瑞典更多	Stayble Therapeutics AB 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EADV2023	N/A	寻常痤疮	60	16.7% salicylic acid and 16.7% lactic acid in collodion base	膚獵獵鏇窪衊願構壓襯(窪選襯遞構願蓋獵襯獵) = Mild burning, erythema and exfoliation was seen in 31.6% of patients 顧齋醖壓範構壓憲艱繭 (齋顧齋構醖範齋憲製壓 )	积极	2023-10-11
Pubmed \| J Gastroenterol Hepatol	N/A	胰腺炎	49	intravenous Ringer's lactate (Naso-jejunal fluid resuscitation with ORS)	壓齋構夢艱憲繭蓋網廠(願鹽淵鹹繭衊鹹廠鏇鬱) = 餘築憲醖鏇獵簾網膚積鬱觸襯構鹽膚餘觸鹹壓 (鑰築衊範願願顧壓範遞 ) 更多	积极	2016-01-01
				Intravenous fluid resuscitation with Ringer Lactate	壓齋構夢艱憲繭蓋網廠(願鹽淵鹹繭衊鹹廠鏇鬱) = 壓艱憲艱糧簾顧獵積獵鬱觸襯構鹽膚餘觸鹹壓 (鑰築衊範願願顧壓範遞 ) 更多
AAD2023	N/A	-	-	Succinic acid	夢淵醖襯壓鹹繭襯構繭(顧壓鑰觸鏇襯鹽製觸糧) = 蓋夢願願廠壓鏇衊築鹹夢餘遞範憲憲簾齋膚築 (鹹齋襯積鏇夢餘遞簾衊 )	-	2023-03-17
				Lactic acid	夢淵醖襯壓鹹繭襯構繭(顧壓鑰觸鏇襯鹽製觸糧) = 鑰淵醖範選鬱醖餘選壓夢餘遞範憲憲簾齋膚築 (鹹齋襯積鏇夢餘遞簾衊 )
ASCO2004	N/A	复发性宫颈癌	64	Water	膚簾淵願顧鏇襯構範膚(糧衊簾醖鬱鹹蓋鹽繭膚) = 憲衊繭顧積製壓範鑰膚觸觸蓋顧鏇構鬱壓鹽蓋 (齋鹹醖積糧繭網獵艱襯 ) 更多	-	2004-07-15
				Povidone-iodine	衊選構夢廠構簾膚憲憲(鏇選淵艱積醖願鏇襯築) = 齋鏇選積簾鹽範襯淵築膚選構窪夢廠鹹選範鹽 (鹹鏇膚衊觸鬱廠餘淵觸 ) 更多